SNCA and synucleinopathy: This highlights the potential of α-synuclein RT-QuIC as a marker of pre-symptomatic/prodromal α-synucleinopathy (with possible contribution to patient selection in clinical trials) once established in greater numbers of mutation carriers and with longitudinal studies, ideally with post-mortem histopathological confirmation (Garrido et al., 2019).